Showing results (271-280 of 353) with videos related to

Sort By:
Pageof 36
The Journal of Sexual Medicine|January 21, 2006
The multinational Men's Attitudes to Life Events and Sexuality (MALES) Study Phase II: understanding PDE5 inhibitor treatment seeking patterns, among men with erectile dysfunctionWilliam A Fisher, Raymond C Rosen, Ian Eardley, et al.
The Journal of Dermatological Treatment|June 11, 2024
Expert consensus on unmet needs, referral criteria and treatment goals for hidradenitis suppurativa in Saudi ArabiaMaysa T Eshmawi, Hajer Yousef Al-Mudaiheem, Mohammed Fatani, et al.
The British Journal of Dermatology|August 12, 2025
The Hidradenitis Suppurativa Symptom and Impact Diary: Development and psychometric evaluation of a novel set of patient reported outcomes for hidradenitis suppurativaJohn R Ingram, Magdalena B Wozniak, Anna Passera, et al.
Journal of Clinical Medicine|February 15, 2022
Microwave Therapy for Cellulite: An Effective Non-Invasive TreatmentLuigi Bennardo, Irene Fusco, Cristina Cuciti, et al.
Dermatology and Therapy|February 8, 2025
Implementation Science to Improve the Diagnosis and Management of Hidradenitis Suppurativa: HELyx Study Design OverviewJohn R Ingram, Georgios Kokolakis, Barry M McGrath, et al.
Patient Related Outcome Measures|June 28, 2017
Initial development of a patient-reported outcome measure of experience with cognitive impairment associated with schizophreniaLisa C Welch, Jeremiah J Trudeau, Steven M Silverstein, et al.
Drug Discovery Today|May 4, 2023
A new era for schizophrenia drug development - Lessons for the futureKiri T Granger, Michael Sand, Sheryl Caswell, et al.
American Journal of Clinical Dermatology|March 10, 2026
Defining Moderate Disease and Progression in Hidradenitis Suppurativa: An Expert Framework to Unlock the Window of Opportunity for Prompt TreatmentAntonio Martorell, John R Ingram, Christopher J Sayed, et al.
Schizophrenia Research|September 5, 2019
Detecting schizophrenia early: Prediagnosis healthcare utilization characteristics of patients with schizophrenia may aid early detectionAnna Wallace, Keith Isenberg, Whitney York, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 4, 2021
Symptomatic and preventive effects of the novel phosphodiesterase-9 inhibitor BI 409306 in an immune-mediated model of neurodevelopmental disordersJoseph Scarborough, Daniele Mattei, Cornelia Dorner-Ciossek, et al.
Pageof 36